With markets having come a long way since November when vaccines were first announced, they could be susceptible to a pull-back if anything threatens to derail the healthcare recovery but on balance, we think there are merits to a small increase in growth asset exposure.

Within growth assets, we also reduce exposure to defensive sectors in favour of more sensitive sectors like industrials and increase in exposure to medium and small sized companies that will continue to benefit from the strengthening economic environment.